trending Market Intelligence /marketintelligence/en/news-insights/trending/sktrxpzaps4foc45hzyflg2 content esgSubNav
In This List

Albertsons' Rite Aid deal clears antitrust hurdle

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Global M&A By the Numbers: Q1 2022

Blog

Anticipate the Unknown: Does Supply Chain Disruption Lead to Increased Credit Risk?

Blog

Insight Weekly: Earnings forecasts for US banks; corporate deleveraging; LatAm currency gains


Albertsons' Rite Aid deal clears antitrust hurdle

Albertsons Cos. Inc. appears to be one step closer to closing its purchase of Rite Aid Corp.

The retail pharmacy chain said in a March 29 statement that federal antitrust regulators had run out of time to request more information about the companies' proposed deal as of 11:59 p.m. on March 28, signaling that the U.S. government will allow the transaction to proceed.

The deal, which would form a single company worth about $24 billion, must now win approval from Rite Aid shareholders, the retailer said. Rite Aid and Albertsons announced the deal in February.

Under the Hart-Scott-Rodino Act, federal antitrust regulators, including the Federal Trade Commission and the U.S. Department of Justice, must request additional information about a deal within certain time frames. If the regulators do not make any requests before the period ends, the deal may proceed.

The Justice Department made such a request of CVS Health Corp. and Aetna Inc. in February. Federal regulators have yet to sign off on that transaction, worth about $69 billion.

Shareholders at both CVS and Aetna voted to approve the deal in mid-March.